Advanced search
Publication Cover
OncoTargets and Therapy Volume 14, 2021 - Issue
Submit an article Journal homepage
68
Views
1
CrossRef citations to date
0
Altmetric
Case Report

Long-Term Survival After Salvage Thoracic Surgery on a Patient with ALK-Rearranged Metastatic Lung Adenocarcinoma After Progression on Targeted Therapy

Kangqi Ren1 Department of Thoracic Surgery, Shenzhen People’s Hospital & The Second Clinical Medical College of Jinan University, Shenzhen, People’s Republic of China
,
Guanggui Ding1 Department of Thoracic Surgery, Shenzhen People’s Hospital & The Second Clinical Medical College of Jinan University, Shenzhen, People’s Republic of China
,
Shuying Xie2 Department of Medicine, Burning Rock Biotech, Guangzhou, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-3986-2746
ORCID Icon &
Lin Yang1 Department of Thoracic Surgery, Shenzhen People’s Hospital & The Second Clinical Medical College of Jinan University, Shenzhen, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0507-3068
ORCID Icon
Pages 5221-5225 | Published online: 02 Nov 2021

References

  • Kim C, Hoang CD, Kesarwala AH, Schrump DS, Guha U, Rajan A. Role of local ablative therapy in patients with oligometastatic and oligoprogressive non-small cell lung cancer. J Thorac Oncol. 2017;12:179–193. doi:10.1016/j.jtho.2016.10.012
  • Ohtaki Y, Shimizu K, Suzuki H, et al. Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment. Lung Cancer. 2021;153:108–116. doi:10.1016/j.lungcan.2020.12.037
  • Hong X, Chen Q, Ding L, et al. Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer. Oncotarget. 2017;8:41631–41640. doi:10.18632/oncotarget.15892
  • Kim ES, Moon J, Herbst RS, et al. Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536. J Thorac Oncol. 2013;8:1519–1528. doi:10.1097/JTO.0000000000000009
  • Schneider BJ, Kalemkerian GP, Gadgeel SM, et al. Phase II trial of dose-dense pemetrexed, gemcitabine, and bevacizumab in patients with advanced, non-small-cell lung cancer. Clin Lung Cancer. 2017;18:299–302. doi:10.1016/j.cllc.2016.11.019
  • Song W, Di S, Liu J, et al. Salvage surgery for advanced non-small cell lung cancer after targeted therapy: a case series. Thorac Cancer. 2020;11:1061–1067. doi:10.1111/1759-7714.13366
  • Weickhardt AJ, Rothman MS, Salian-Mehta S, et al. Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer. 2012;118:5302–5309. doi:10.1002/cncr.27450
  • Friedlaender A, Banna G, Patel S, Addeo A. Diagnosis and treatment of ALK aberrations in metastatic NSCLC. Curr Treat Options Oncol. 2019;20:79. doi:10.1007/s11864-019-0675-9
  • Wu X, Wang W, Zou B, et al. Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: a case report. Thorac Cancer. 2020;11:1695–1698. doi:10.1111/1759-7714.13389
  • Guo J, Shi J, Yao M, et al. A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib: a case report. Medicine. 2020;99:e22631. doi:10.1097/MD.0000000000022631
  • Wu X, Zhou H, He Z, et al. Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report. Transl Lung Cancer Res. 2020;9:2494–2499. doi:10.21037/tlcr-20-1049
  • Luo J, Gu D, Lu H, Liu S, Kong J. Coexistence of a novel PRKCB-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to crizotinib. J Thorac Oncol. 2019;14:e266–e268. doi:10.1016/j.jtho.2019.07.021
  • Qin BD, Jiao XD, Liu K, Wu Y, Zang YS. Identification of a novel EML4-ALK, BCL11A-ALK double-fusion variant in lung adenocarcinoma using next-generation sequencing and response to crizotinib. J Thorac Oncol. 2019;14:e115–e117. doi:10.1016/j.jtho.2019.01.032
  • Zhang C, Wang L, Li W, et al. Surgical outcomes of stage IV non-small cell lung cancer: a single-center experience. J Thorac Dis. 2019;11:5463–5473. doi:10.21037/jtd.2019.11.30
  • Weickhardt AJ, Doebele RC, Camidge DR. A time to test, a time to treat. J Thorac Dis. 2012;4:223–225.
  • Ni Z, Wang X, Zhang T, Jin RZ. Molecular dynamics simulations reveal the allosteric effect of F1174C resistance mutation to ceritinib in ALK-associated lung cancer. Comput Biol Chem. 2016;65:54–60. doi:10.1016/j.compbiolchem.2016.10.005
  • Gainor JF, Dardaei L, Yoda S, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016;6:1118–1133. doi:10.1158/2159-8290.CD-16-0596

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.